SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Singh, VistaGen's Chief Executive Officer, will present at the 2019 ChinaBio Partnering Forum held at the Kerry Hotel Pudong in Shanghai, China, on Wednesday, May 8, 2019 at 3:00 p.m. China Standard Time.
For more information regarding the conference, or to schedule a one-on-one meeting with VistaGen's management team, please contact the Company's representative in China, Greg Scott, CEO of ChinaBio at Greg.Scott@ChinaBio.com.
About VistaGen
VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen's CNS pipeline includes three drug candidates with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety.
For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
Company Contact
Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com
Investor Contact
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com
Media Contact
Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com
SOURCE: VistaGen Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/544439/VistaGen-Therapeutics-to-Present-at-ChinaBioR-Partnering-Forum-in-Shanghai-China
